• Illumina Releases International Version of Tertiary Clinical NGS Analysis Software

    Bio-IT World | Illumina has released Connected Insights, a cloud-based software for tertiary analysis for clinical next-generation sequencing (NGS) data. The software is commercially available in a limited number of countries and in beta testing in the US.

    Mar 29, 2023
  • Genome Citation Service Tracks Genomes Across Research

    Bio-IT World | Kjiersten Fagnan, chief informatics officer at Lawrence Berkeley National Laboratory’s Joint Genome Institute appears on the Trends from the Trenches podcast to speak with host Stan Gloss of BioTeam about the JGI’s Genome Citation Service, a new offering that connects the broader community with the organization’s data resources and infrastructure.

    Mar 28, 2023
  • Follow the Money: Recombinase Platform Unlocks Full Potential of Gene Editing, Lead Drug Candidate Clears Neurodegenerative Toxins, More

    Bio-IT World | Funding pipeline advancement of first-in-class extracellular protein degraders, a proteomics AI-based platform that comprehensively maps the course of a disease, a proprietary computational antibody drug discovery platform that uses machine learning to model antibody-antigen interactions, and more.

    Mar 28, 2023
  • PacBio Releases Computational Tool for Parsing Pseudogenes

    Bio-IT World | PacBio last week announced a new informatics method that genotypes gene paralogs and pseudogenes with high accuracy. The computational tool, named Paraphase, enables variant calling, copy number analysis and phasing by identifying the full gene sequence of each of the haplotypes for all genes and pseudogenes of the same gene family.

    Mar 24, 2023
  • Neighborhood Analysis Highlights Role Of Macrophages In ER+ Breast Cancers

    Bio-IT World | When it comes to breast cancer, the most commonly occurring estrogen receptor-positive (ER+) variety is a poor candidate for treatment with conventional immunotherapies designed to help the patient’s own immune system fight back. Unlike triple-negative breast cancer, ER+ tumors don’t have many infiltrating T cells so potentiating their function alone doesn’t make much of a difference.

    Mar 22, 2023